Studies have shown that PTGS2 participates in the pathogenesis of migraines, and the symptoms of migraine patients can be improved by inhibiting the PTGS2 proinflammatory pathway and reducing the levels of TNF-α, IL-2, and IL-6 [46]. This evidence concerns the gene IL6 and migraine disorder.